SNDX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
72.8M
+12.2%
64.9M
-5.6%
68.7M
+49.8%
45.9M
+20.8%
38.0M
Cost of Revenue
3.2M
+21.8%
2.6M
-2.7%
2.7M
+28.9%
2.1M
+64.2%
1.3M
Gross Profit
69.6M
+11.8%
62.2M
-5.7%
66.0M
+50.8%
43.8M
+19.3%
36.7M
Operating Expenses
109.6M
+1.2%
108.3M
+3.7%
104.4M
-4.7%
109.5M
+3.3%
106.0M
R&D
68.0M
+15.6%
58.8M
-25.2%
78.6M
+39.7%
56.3M
-9.6%
62.2M
SG&A
41.5M
+10.5%
37.6M
-24.7%
49.9M
+11.2%
44.9M
+2.5%
43.8M
Operating Income
-39995000
+13.1%
-46048000
-20.0%
-38362000
+41.6%
-65709000
+5.3%
-69353000
EBITDA
-39990000
+13.1%
-46044000
-20.0%
-38359000
+41.6%
-65709000
+5.3%
-69353000
Net Income
-49363000
-15.7%
-42673000
+37.3%
-68014000
-12.0%
-60715000
+15.5%
-71847000
EPS (Basic)
$-0.55
-14.6%
$-0.48
+38.5%
$-0.78
-11.4%
$-0.70
+15.7%
$-0.83
EPS (Diluted)
$-0.55
-14.6%
$-0.48
+38.5%
$-0.78
-11.4%
$-0.70
+15.7%
$-0.83
Shares (Diluted)
89.0M
+0.8%
88.3M
+1.0%
87.4M
+0.9%
86.6M
+0.3%
86.3M
Syndax Pharmaceuticals (SNDX) โ€” Financials